CP 690,550,
CP 690550,
CP-690,550,
CP-690550,
CP690550,
tasocitinib,
tofacitinib,
tofacitinib citrate,
Xeljanz,
Tofacitinib citrate,
540737-29-9,
Tasocitinib citrate,
Xeljanz,
Tofacitinib (citrate),
Tofacitinib (CP-690550) Citrate,
UNII-O1FF4DIV0D,
CP-690550 citrate,
O1FF4DIV0D,
CHEBI:71197,
CP-690550-10,
CP-690,550-10,
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate,
CP 690550 citrate,
Tofacitinib citrate [USAN],
Xeljanz Xr,
citro; tofacitinib,
3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate,
3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate salt,
3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile citrate salt,
CEP-18770(Delanzomib),
MLS006010058,
SCHEMBL1374185,
CHEMBL2103743,
Tofacitinib citrate (JAN/USAN),
DTXSID80202404,
EX-A204,
Tofacitinib citrate(CP690550),
SYIKUFDOYJFGBQ-YLAFAASESA-N,
C22H28N6O8,
AOB87768,
HY-40354A,
s5001,
AKOS022178222,
CP-690550 - Tofacitinib citrate,
Tofacitinib citrate, >=98% (HPLC),
API0017273,
CS-0928,
PB31590,
1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)- beta-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1),
AC-25004,
AS-19392,
BC600313,
SC-12808,
SMR004701220,
AB0033779,
AX8223835,
Tofacitinib citrate (CP-690550 citrate),
ST24050181,
X7518,
D09783,
Q-3287,
(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile citrate,
(3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate,
(3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-1-PIPERIDINEPROPANENITRILE CITRATE SALT,
1-PIPERIDINEPROPANENITRILE,4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-,(3R,4R)-,2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE(1:1),
2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile,
3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile mono citrate salt,
3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt,
Xeljanz (TN),
tofacitinib citric acid,
CP-690550,
540737-29-9 (citrate),
MFCD11616529,
ACN-037647,
CID10174505,
CID 10174505,
CP690550,
Tofacitinib citrate, 99% - 10MG 10mg,
C16-H20-N6-O.C6-H8-O7,
CP 690550,
CP-690550 Citrate (Tofacitinib Citrate),
A4135,
CP-690,550,
CP 690550-10,
1-PIPERIDINEPROPANENITRILE,4-METHYL-3- -BETA-OXO-, -,2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE,
477600-75-2,